Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Grifols, S.A. GRFS
$8.67
-$0.01 (-0.17%)
На 18:00, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
7241066703.00000000
-
week52high
13.34
-
week52low
5.71
-
Revenue
6063967000
-
P/E TTM
22
-
Beta
0.42977000
-
EPS
0.33000000
-
Last Dividend
3.04350000
-
Next Earnings Date
13 мар 2023 г. в 04:00
Описание компании
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Deutsche Bank | Hold | Buy | 05 ноя 2021 г. |
| Credit Suisse | Outperform | Neutral | 23 мар 2021 г. |
| HSBC | Buy | Hold | 11 мар 2021 г. |
| Santander | Buy | Hold | 28 окт 2019 г. |
| JP Morgan | Overweight | Neutral | 27 июн 2019 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Grifols, S.A. (GRFS) Q1 2023 Earnings Call Transcript
Seeking Alpha
09 мая 2023 г. в 22:36
Grifols, S.A. (NASDAQ:GRFS ) Q1 2023 Earnings Conference Call May 9, 2023 8:30 AM ET Company Participants Nuria Pascual - IR Thomas Glanzmann - Executive Chairman Victor Grifols Deu - Co-CEO Alfredo Arroyo - CFO Conference Call Participants Jo Walton - Credit Suisse James Gordon - JP Morgan Guilherme Sampaio - CaixaBank BPI Tom Jones - Berenberg Jaime Escribano - Banco Santander Charles Pitman - Barclays Vineet Agrawal - Citi Nuria Pascual Hello, everyone, and welcome to the Grifols First Quarter 2023 conference call.
Why Shares of Grifols Were Up Tuesday
The Motley Fool
09 мая 2023 г. в 15:39
Grifols' first-quarter report came a day after it announced a new leadership team. The company upgraded half-year and full-year guidance.
Grifols (GRFS) Upgraded to Strong Buy: Here's Why
Zacks Investment Research
07 мар 2023 г. в 13:32
Grifols (GRFS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Is Grifols (GRFS) Stock Undervalued Right Now?
Zacks Investment Research
27 февр 2023 г. в 11:17
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Grifols: A Favorite For Some, Speculative Buy For Me
Seeking Alpha
22 февр 2023 г. в 23:46
Grifols is a global, Spanish-based biotech company that is a favorite for many European investors, despite the fact that the company does not pay a dividend. It's one of the more well-known Spanish companies on the world stage, with headquarters in Barcelona, an 80+ year history under its belt, and employing over 20,000 people.